SCHEMBL6501693

SCHEMBL6501693

CCc1ccc(C2=C(C(=O)Nc3ccc4c(c3)CCN(CCNC(C)=O)C4)CCCC2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.54
▸ KMT2A Q03164 2/20 0.54
▸ TP53 P04637 1/20 0.54
▸ ALOX15 P16050 1/20 0.54
▸ MAPT P10636 2/20 0.43
▸ HSP90AA1 P07900 1/20 0.43
▸ NPC1 O15118 1/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ ABCB1 P08183 6/20 0.42
▸ TNF P01375 1/20 0.41
▸ NOD1 Q9Y239 1/20 0.41
▸ PLAU P00749 1/20 0.41
▸ KDM4E B2RXH2 1/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ CYP2D6 P10635 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ ITGB3 P05106 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6492509 0.92 PLAU (0.47) MEN1KMT2ATP53ALOX15MAPT
SCHEMBL6491779 0.89 ACACB (0.43) MEN1KMT2ATP53ALOX15HSP90AA1
SCHEMBL20884113 0.80 MEN1 (0.58) MEN1KMT2ATP53ALOX15MAPT
SCHEMBL6489620 0.75 ABCB1 (0.51) ABCB1TNFNOD1DRD2ABCG2
SCHEMBL6649528 0.74 MEN1 (0.48) MEN1KMT2ATP53ALOX15MAPT
SCHEMBL691418 0.72 MTTP (0.59) MAPTKDM4E
SCHEMBL6496773 0.72 ABCB1 (0.40) ABCB1TNFNOD1ITGB3ITGA2B
Hydrochloric Acid SCHEMBL8408661 0.72 MTTP (0.59) MAPTKDM4E
Hydrochloric Acid SCHEMBL3887925 0.72 MTTP (0.59) MAPTKDM4E
SCHEMBL20909873 0.71 SIGMAR1 (0.58) MEN1KMT2ATP53ALOX15MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 — — US disclosed
EP-1472226-A1 HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-11-03 — — EP disclosed
WO-2003045921-A1 HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-06-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 MEN1 1991/4885KMT2A 573/4885TP53 3031/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback